The contract development and manufacturing organization (CDMO) industry has seen significant advancements and partnerships as of January 2025. With a focus on large molecules and advanced therapies, this article delves into the latest developments, highlighting key trends, common themes, and
The Blood and Cell Advocacy Register (BCAR) is a newly launched consortium that aims to revolutionize the development and commercialization of advanced therapy medicinal products (ATMPs). Formed in December 2024, BCAR brings together experts and organizations from the blood and cell industries to
The field of biochemical engineering is witnessing an innovative approach with the development of fine-bubble engineering techniques. By focusing on the manipulation of both nanobubbles (NBs) and microbubbles (MBs), researchers aim to improve the efficiency and effectiveness of various bioprocess
The landscape of therapeutic drugs is undergoing a transformative phase, driven by significant strides in bioprocessing technologies and innovative biotechnological advancements. One of the most notable developments in recent years has been the shift towards personalized medicine, which tailors
In a strategic move to tackle severe blood cancers, Alanis Therapeutics (ATI) has teamed up with KBI Biopharma to enhance the development and manufacturing of ATI's preclinical antibody candidate, ATI-D1. This partnership aims to accelerate the treatment of myelodysplastic syndromes (MDS) and acute
The upstream bioprocessing market is experiencing unprecedented growth, driven by a confluence of factors that are reshaping the landscape of biopharmaceutical production. Valued at 22.79 billion USD in 2023, the market is projected to surge to 82.10 billion USD by 2032, expanding at a compound
